MedTrace Logo

Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer

NCT01171729 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2010-08-11

No results posted yet for this study

Summary

This is an open label, Phase I/IIa trial of immunotherapy with CreaVax-PC as treatment in men with hormone-Refractory Metastatic Prostate Cancer.

Conditions

  • Prostatic Cancer

Interventions

BIOLOGICAL

Autologous dendritic cell

Autologous dendritic cells pulsed with prostate cancer antigen and KLH

Sponsors & Collaborators

  • National Cancer Center, Korea

    collaborator OTHER_GOV

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • J C W, M.D,Ph.D · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01171729 on ClinicalTrials.gov